anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTELENCE ®(etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). 

The chemical name for etravirine is 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile. Its molecular formula is C 20H 15BrN 6O and its molecular weight is 435.28. Etravirine has the following structural formula: 

Etravirine is a white to slightly yellowish-brown powder. Etravirine is practically insoluble in water over a wide pH range. It is very slightly soluble in propylene glycol and slightly soluble in ethanol. Etravirine is soluble in polyethylene glycol (PEG)400 and freely soluble in some organic solvents (e.g., N,N-dimethylformamide and tetrahydrofuran).

INTELENCE ®25 mg tablets are available as white to off-white, oval scored tablets for oral administration. Each 25 mg tablet contains 25 mg of etravirine and the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate and microcrystalline cellulose. 

INTELENCE ®100 mg tablets are available as white to off-white, oval tablets for oral administration. Each 100 mg tablet contains 100 mg of etravirine and the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate and microcrystalline cellulose. 

INTELENCE ®200 mg tablets are available as white to off-white, biconvex, oblong tablets for oral administration. Each 200 mg tablet contains 200 mg of etravirine and the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose and silicified microcrystalline cellulose.
Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
Macrophages play crucial roles in the innate immune response, exhibiting context-dependent behaviors. Within the tumor microenvironment, macrophages exist as tumor-associated or M2-like macrophages, presenting reprogramming challenges. In this study, we develop a peptide hydrogel that is able to polarize M0 macrophages into pro-inflammatory M1 macrophages through the activation of NF-κB signaling pathways. Importantly, this system is also found to be capable of reprogramming M2 macrophages into pro-inflammatory M1-like macrophages by activating CD206 receptors. The nanofibrous hydrogel self-assembles from a short peptide that contains an innate defense regulator peptide and a self-assembly promoting motif, presenting densely arrayed regulators that multivalently engage with macrophage membrane receptors to not only polarize M0 macrophages but also repolarize M2 macrophages into M1-like macrophages. Overall, this work offers a promising strategy for reprogramming macrophages, holding the potential to enhance immunotherapy by remodeling immune-resistant microenvironments.
Stannogluconic acid, free from objectionable colour, taste and odour, is prepared by mixing an aqueous solution of gluconic acid or gluconolactone with stannous hydroxide, and treating the aqueous solution formed with activated carbon.  A base e.g. a hydroxide, carbonate or bicarbonate of ammonium, an alkali metal or an alkaline earth metal may be added after the treatment with active carbon to form a salt. The stannous hydroxide is preferably freshly prepared, and the mixing is performed at between 20 DEG  and 50 DEG C.  The activated carbon may be removed by filtration through diatomaceous earth.  The acid or the salt thereof may be used in the preparation of a dentifrice.ALSO:A dentrifice comprises stannoghiconic acid or salts thereof, free from objectionable colour, taste and odour, prepared by mixing aqueous gluconic acid or gluconolactone with stannous hydroxide and treating the aqueous solution with activated carbon (see Division C2).  Sodium or ammonium gluconate is preferred and 0.1-5 parts may be mixed with 100 parts of a paste base comprising 25-55% abrasive e.g. calcium pyrophosphate, 1-5% sudsing agent e.g. sodium lauryl sulphate, 1-5% thickening agent e.g. sodium carboxymethyl cellulose, 5-35% humectant flavouring e.g. oil of spearmint, or 100 parts of a powder base comprising 65-95% abrasive, 1-5% sudsing agent and flavouring.  An example describes a dentifrice containing sodium stannogluconate, calcium pyrophosphate, sodium carboxymethyl cellulose, magnesium aluminium silicate, sorbitol glycerine, sodium lauryl sulphate, saccharin, flavour and water.
Procedure for obtaining preparation, in the subject of this invention, is carried in the way that 1 kg of milk acid is poured in the appropriate vessel that is equipped by a mechanical mixer, the acid is warmed to 98°C and with mixing in the vessel it adds 0.750 kg of salicile acid. When the salicile acid is completely dissolved the vessel is cooled up to 20°C, and then added along with mixing 5 ml. 3.6 % of hydrogen peroxide and continue with mixing for another 10 minutes. In so obtained mixture 20 ml of 10 % solution of collodium in the ether and 50 g of starch and the content in the ballon are mixed for another 30 minutes. At the ending the content from the vessel is poured out in the opened vessel and remained in digestorium for 24 hours with occasional mixing. The yield is rich. Preparation obtained from this procedure is used for healing the warts, callouses and other callosities both in the human and in veterinary medicine.
This study aims to explore the molecular mechanisms and associated pathways of myocardial infarction (MI). We employed a variety of analytical methods, including Mendelian Randomization (MR) analysis, transcriptome microarray data analysis, gene function and pathway enrichment analysis, untargeted metabolomic mass spectrometry analysis, and gene-metabolite interaction network analysis. The MR analysis results revealed a significant impact of mitochondrial DNA copy number on MI and coronary artery bypass grafting. Transcriptome analysis unveiled numerous differentially expressed genes associated with myocardial ischemia, with enrichment observed in cardiac function and energy metabolism pathways. Metabolomic analysis indicated a significant downregulation of mitochondrial regulation pathways in ischemic myocardium. T500 metabolite quantification analysis identified 90 differential metabolites between MI and Sham groups, emphasizing changes in metabolites associated with energy metabolism. Gene-metabolite interaction network analysis revealed the significant roles of key regulatory molecules such as HIF1A, adenosine, TBK1, ATP, NRAS, and EIF2AK3, in the pathogenesis of myocardial ischemia. In summary, this study provides important insights into the molecular mechanisms of MI and highlights interactions at multiple molecular levels, contributing to the establishment of new theoretical foundations for the diagnosis and treatment of MI.
The invention provides a staphylococcus sciuri, a vaccine and a preparation method thereof, belonging to the technical field of biotechnology. The collection number of the staphylococcus sciuri NJ1306 provided by the invention is CCTCC NO: M2013702. Experiments prove that the staphylococcus sciuri NJ1306 has pathogenicity on BALB/c mice and piglets. The invention also provides a staphylococcus sciuri inactivated vaccine containing an inactivated NJ1306 strain. A staphylococcus sciuri inactivated oil emulsion vaccine is prepared by uniformly mixing an inactivated staphylococcus sciuri culture solution and an adjuvant. By adopting the inactivated oil emulsion vaccine prepared by adopting the staphylococcus sciuri NJ1306 disclosed by the invention, good protection capacity can be provided for the BALB/c mouse, so that the strain is proved to have good immunogenicity.
Site providers will be trained to efficiently discuss school-supervised medication administration with families and school nurses. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment in Asthma Link to provide school-supervised asthma therapy. Ongoing communication occurs between the pediatric practice, school nurse and families through electronic medical record messaging and phone communication. Data will be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
Certain example embodiments provide systems and methods for providing clinical element extraction, holding, and transmission in a widget-based application. An example clinical data element communicator system includes a user interface including clinical content retrieved from a plurality of clinical information sources for graphical display to a user. The user interface facilitates user interaction with the displayed clinical content, the clinical content including applications and patient data. The example system also includes a holding area for clinical content and a transmission unit for transmitting the clinical content to one or more recipients. The holding area is displayed as part of the user interface and holds clinical content selected by the user and deposited in the holding area. The clinical element transmission unit receives the clinical content deposited in the holding area, packages the clinical content, and transmits the clinical content in an electronic data message to one or more recipients.
The oral LD50 of spironolactone is greater than 1000 mg/kg in mice, rats, and rabbits.

Acute overdosage of CAROSPIR may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Rarely, instances of hyponatremia, hyperkalemia, or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage. Hyperkalemia may occur, especially in patients with impaired renal function.

Treatment: Induce vomiting or evacuate the stomach by lavage. There is no specific antidote. Treatment is supportive to maintain hydration, electrolyte balance, and vital functions. Patients who have renal impairment may develop hyperkalemia. In such cases, discontinue CAROSPIR.
Procalcitonin has been investigated as a marker for bowel ischemia. This study examined the role of procalcitonin in predicting failure of non-operative management (NOM) in bowel obstructions. Patients with bowel obstructions at a single center from August 2022 to January 2023 were prospectively enrolled (n = 79). Lactic acid (LA) and procalcitonin were collected after surgical consultation. The primary outcome was success or failure of NOM. Univariate analysis, multivariable logistic regression, and performance measures of procalcitonin and LA in predicting bowel ischemia was performed. Of 79 patients included, 48 (61%) required operative intervention during index admission. There were no significant differences in demographics, comorbidities, procalcitonin, nor LA between groups. Time from last bowel movement was associated with failure of NOM (OR 1.03 [95% CI 1.01-1.06]; P = .008), though initial procalcitonin or LA was not. Procalcitonin >.3 ng/mL had acceptable sensitivity in screening for bowel ischemia.
The present invention relates to a pharmaceutical composition capable of being used to effectively prevent and treat autoimmune diseases caused by an immune hypersensitivity reaction. According to the present invention, a saucerneol D compound derived from Saururus chinensis Baill. has excellent effects in inhibiting generation of nitrogen oxide caused by maturation of dendritic cells; inhibiting expression of surface molecules; inhibiting endocytosis; inhibiting cytokine secretion; inhibiting migration of dendritic cells; inhibiting expression of signal transduction substances activated in a maturation process; and inhibiting activation of T cells. Therefore, according to the present invention, a composition comprising a saucerneol D compound as an active ingredient ultimately reduces an immune reaction effectively by inhibiting maturation of dendritic cells. Accordingly, the composition can be practically used as an immunosuppressant capable of preventing or treating diseases such as autoimmune diseases caused by an immune hypersensitivity reaction. The composition comprises a saucerneol D compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
PURPOSE:To prevent Salmonella infectious disease, by administering a preventive consisting of an inactivated Salmonella mold and streptomycin or a salt thereof continuously. CONSTITUTION:A preventive for Salmonella infectious disease consisting of an inactivated Salmonella mold and 1-100wt% based on the mold of streptomycin or a salt thereof. Salmonella infectious disease is prevented by continuously and orally administering the preventive every day, preferably for >=a week. The preventive may be added to feeds or foods. Referring to a dose, the amount of the inactivated mold is at least 2mg/day/kg (calculated as wet mold amount) and the amount of streptomycin is 1-100wt% based on the inactivated mold. Solution, powder, granule, tablet, coated tablet, capsule, pill, etc., may be cite as the dosage form. Toxicity is hardly observed and side effects are also hardly produced because the amount of streptomycin used is extremely small.
A novel bacterial extract comprises ribonucleic acid and ribosomal proteins of Klebsiella pneumoniae, Diplococcus pneumoniae, Streptococcus pyrogenes Gr.A and Haemophilus influenzae and proteoglycines of the Klebsiella pneumoniae membrane. The ribonucleic acid and ribosomal protein components are obtd. by subjecting residues of the microorganisms to centrifuging, treatment with deoxyribonuclease, ultracentrifuging and to pptns. with EtOH alternated with solubilisation in a pH 4 phosphate buffer soln. contg. MgCl2, NaCl and sodium dodecyl sulphate followed by sterilisation and lyophilisation. The proto proteoglycines of the K.pneumoniae membrane are obtd. by sepg. a fraction of the membrane residues from the ribosomal fraction by centrifuging and subsequent purification by washing centrifuging and ultracentrifuging.
Embodiments are directed towards a machine learning repository for managing machine learning (ML) model envelopes, ML models, model objects, or the like. Questions and model objects may be received by a ML model answer engine. Machine learning (ML) model envelopes may be received based on the questions. The model objects may be compared to parameter models associated with the ML model envelopes. ML model envelopes may be selected based on the comparison such that the model objects satisfy the parameter models of each of the selected ML model envelopes. ML models included in each selected ML model envelope may be executed to provide score values for the model objects and the score values may be included in a report.
Administration of a time-controlled, pulsatile-release caffeine formulation (160 mg caffeine) at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
PURPOSE: A composition containing a Rhus verniciflua Stokes extract for preventing and treating cholesterolemia is provided to prevent or treat hyperlipidemia and fatty liver using an ethyl acetate fraction and a single material of the extract. CONSTITUTION: A composition for preventing and treating cholesterolemia contains a Rhus verniciflua Stokes extract as a main ingredient. A composition for promoting hair growth and preventing alopecia contains the extract as an active ingredient. A health functional food for promoting hair growth and preventing alopecia contains a hot water extract of Rhus verniciflua Stokes. The health functional food is fustin(3,3',4',7-tetrahydroxyflavanone) with a white crystalline form which is fractioned from the hot water extract. [Reference numerals] (AA) Rhus verniciflua Stokes; (BB) Hot water extraction; (CC) Secondary treatment; (DD) Spray-drying; (EE) Rhus verniciflua Stokes extracted powder; (FF) Extraction twice after pulverization; (GG) C1-4 low grade alcohol or ethanol; (HH) Dextrin addition;
Research has documented positive effects of doctor-patient race concordance. Given the low representation of minorities among doctors in the US, this evidence suggests that the path to addressing well-documented racial health disparities involves both increasing diversity among healthcare professionals and improving the quality of interactions in race-discordant doctor-patient relationships. Increased focus on improving minority representation among healthcare professionals, and especially among doctors, naturally raises questions about the equilibrium effects of such initiatives. In this study, the investigators aim to explore one potential avenue for equilibrium effects. A growing literature examines how doctors' behavior and beliefs change with patient race and potentially affect the quality of healthcare interactions. This project examines whether and how patients vary their perceptions of the quality of doctors based on race. Significant variation in the perceived quality of minority healthcare professionals could adversely affect the quality and effectiveness of healthcare interactions involving these professionals. Moreover, the range of potential negative patient attitudes that could be encountered in day-to-day clinical practice may also be considered an anticipatory tax and another barrier for prospective minority trainees.

This projects aim to test the following hypotheses: (1) whether subjects believe Black experts are less educated compared with White experts; (2) whether subject believe Black experts are lower quality compared with White experts; (3) whether there is any variation in these two outcomes based on respondent race. The investigators also explore a potential mechanism by examining the extent to which differences in patients' beliefs about the likely occupation of individuals explains differences in patients' beliefs about educational attainment and quality. In this case, the investigators hypothesize that the race of the individual in the photo may be affecting the weight that individuals put on the "expert attire" treatment.
The present invention relates to a capsule for treating prolapse of lumbar intervertebral disc and a preparation method thereof. The capsule for treating prolapse of lumbar intervertebral disc is mainly composed of cassia twigs, dried ginger, asarum heterotropoides fr. schmidt var. Mandshuricum maxim. Kitag., licorice roots, Chinese ephedra, prepared radix aconiti carmichaeli and prepared kusnezoff monkshood roots. The preparation method provided by the present invention comprises: the raw materials are weighed, pulverized, sterilized and loaded into capsules, and each capsule contains 0.555 grams of crude drugs. The present invention has good curative effect and little side effect on prolapse of lumbar intervertebral disc, the clinical cure rate is 80% to 98%, the adopted traditional Chinese medicines have low cost, and the present invention is suitable for popularization and application.
Participants will receive MK-1084 daily oral dose. Additionally, participants receive an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle, oxaliplatin (per label) for first 6 cycles, and leucovorin (per label) and 5-fluorouracil (per label) once every 14-days.
Nocturnal hypoglycemia is a significant side effect of insulin replacement therapy and can lead to many problems including coma and death in the most extreme cases and deterioration of glycemic control. Strategies to prevent nocturnal hypoglycemia include development of newer insulins and delivery systems and the use of specific bedtime snack compositions. Detection of nocturnal hypoglycemia, as it occurs in everyday life, has been a problem since most episodes go unnoticed and therefore untreated leading to a very dangerous situation. With the recent availability of technology which allows for continuous glucose monitoring , it has been made possible to detect nocturnal hypoglycemia as it occurs in daily life. As well, this technology allows for the possibility of better titration of therapy.

Therefore, the goal of our study was to use continuous glucose monitoring technology as a tool to optimize titration of insulin therapy and as a means to detect nocturnal hypoglycemia as it occurs in daily life. Specifically, we sought to compare the use of insulin pump therapy with no bedtime snacks and using a new type of insulin called an analogue(lispro) versus multiple daily injections of insulin, using the same type of insulin analogue, and with and without bedtime snacks. Therefore, we compared 3 groups: 1) insulin pump with no bedtime snacks; 2) multiple injections with bedtime snacks and 3) multiple injections with no bedtime snacks. The groups were primarily compared for the occurrence and frequency of nocturnal hypoglycemia. Other comparisons included: long term glycemic control (A1c), weight and body composition and quality of life.
PURPOSE: We describe a case of intraocular inflammation and palpable purpura in a patient with Pasteurella multocida pneumonia.
METHODS: A 75-year-old pseudophakic woman with type-2 diabetes and chronic obstructive pulmonary disease complained of lower limb palpable purpura and right vision loss of five-day duration. On admission, right visual acuity was hand motion. Slit-lamp examination disclosed severe conjunctival and ciliary injection, corneal oedema, 3-mm hypopyon with heavy fibrin accumulation and blood clots, and synechiae to the IOL.
RESULTS: Chest computed tomography revealed interstitial pneumonia. Sputum culture yielded P. multocida. Amoxicillin/clavulanic tablets (1 g × 3/daily) and topical and systemic steroids were given. Later on, fluorescein angiography showed multiple choroidal lesions bilaterally. With the above-mentioned therapy, there was full recovery of the skin, lung, and eye lesions.
CONCLUSION: This report emphasizes that P. multocida infection should be considered in patients with intraocular inflammation, palpable purpura, and interstitial pneumonia. A multidisciplinary approach is necessary for a correct diagnosis and management.
To facilitate data collection of a short-term intervention, the investigators chose to enroll patients from a mixed physical therapy/chiropractic practice with demographic and economic diversity in the metro Washington area. The neuromodulatory device will have patient controlled frequencies at 50Hz, 100Hz, and 180Hz attached to a 12 x 22 cm metal plate ergonomically curved to fit the low back. The device will be wearable with a neoprene belt on both sides for patients to adjust pressure. The metal pocket in our device holds a 221g clay pack capable of being frozen to 15F or heated to 110F or patient tolerance, with 30 minute thermal capacity. A convenience sample of 10 patients at the clinic was invited to give feedback on the prototype device after informed consent. Changes suggested were incorporated and after informed consent a second group of ten gave will give feedback with the production-ready device.
The present invention relates to photostable compositions that provide protection from ultraviolet radiation ("UVR"). The invention particularly relates to the sunscreens avobenzone, octocrylene and oxybenzone, forming a triplet combination. Compositions of the present invention are free of diesters or polyesters of naphthalene dicarboxylic acid and also are substantially free of substantial amounts of other sunscreens and substantial amounts of optimizing agents. Sunscreens of the invention may be essentially free of, or free of, lower monohydric alcohol and/or acrylates/C12-22 alkylmethacrylate copolymer in an effective non-pilling amount used to gel a C1-C4 alcohol. The triplet combination surprisingly provides and substantially maintains the initial SPF value of the sunscreen composition throughout the period of UVR exposure. Compositions of the invention are photostable such that each of sunscreen active in the triplet combination does not appreciably photodegrade. The present invention accurately communicates the amount of UVR photoprotection actually provided in natural sunlight.